Drug
Ro5083945
Ro5083945: highest development phase Phase 1, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| RO5083945 NCT00721266 | Phase 1 | Neoplasms |
Latest
No recent events.
Follow Ro5083945 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.